



Looking at the World through a different Lens

API PRODUCT LIST

Reaching People. Touching Lives.





LOOKING AT THE WORLD THROUGH A DIFFERENT LENS

What is the use of innovation if it is not accessible, what is the use of accessibility if it is not affordable? Healthcare is all about balance, and we are continuously striving to achieve this balance. Because in our mission to make the world a Happier, Healthier place we know that making a positive difference is the only way of creating an impactful, global healthcare organization that the world can look up to.

ABOUT US

Sun Pharma is the 5th largest generic pharmaceutical company in the world and ranks topmost in India. A vertically integrated business with economies of scale and an extremely skilled team enables timely delivery of quality products at affordable prices. It serves customers and patients in over 150 countries across the globe. Sun Pharma's global presence is supported by 41 manufacturing facilities spread across 5 continents with a multi-cultural workforce comprising over 50 nationalities.

The consolidated revenues for 12 months ending March 2018 are US\$ 4 billion, of which USA contributes US\$ 2.3 billion. In India, the company enjoys leadership across 13 different therapeutic classes of doctors. Sun Pharma's 32 brands feature amongst the top 300 pharmaceutical brands in India. It's footprint across emerging markets covers over 100 markets including 6 markets in Western Europe. It's Global Consumer Healthcare business is ranked in the Top 10 across 4 global markets. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities with 2,000 scientists and R&D investments of over 7% of net sales.


Sun Pharma's product list includes complex APIs that require isolated manufacturing area like anti-cancers, peptides, steroids, sex hormones and controlled/narcotic substances. It offers Bulk Actives, Intermediates and services for Custom Synthesis. Every year, the company makes a large number of products filings based on the technology developed at its R&D centres. Sun Pharma manufactures APIs in 12 world class manufacturing plants located in India, Hungary, the US, Australia and Israel. These manufacturing facilities are cGMP compliant and hold approvals from global regulatory agencies including USFDA, EUGMP, PMDA, COFEPRIS, TGA, etc.

The company currently has 430 DMF/CEP filed, of which 313 have been approved as on June 2018.

Sun Pharma's comprehensive end to end support ensures smooth development, timely filing and successful launch of products. Its R&D prowess and manufacturing capabilities are strengthened by a strong and well informed regulatory team. It has an experienced team of IP attorneys and other skilled professionals, specialising in medicinal chemistry and IP law who protect its IP wealth. This team ensures that all the API and processes developed for global markets comply with applicable laws and intellectual properties.

With its vision of **Reaching People and Touching Lives** globally and as a leading provider of valued medicines, Sun Pharma is dedicated to bring about change and create a meaningful impact in the lives of others.

F I N A N C I A L S N A P S H O T S



Numbers as of March 31, 2018

NEW PRODUCTS

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Abaloparatide*	Anti-Osteoporosis	PN	[247062-33-5]	
Abiraterone Acetate*	Anti-Cancer	PN	[154229-18-2]	▲
Acalabrutinib*	Anti-Cancer	PN	[1420477-60-6]	
Acotiamide*	Gastroprokinetics	PN	[773092-05-0]	
Afatinib Dimaleate*	Anti-Cancer	PN	[850140-73-7]	▲
Albuterol Sulphate*	Anti-Asthmatic	EP	[5122-70-9]	
Alecicib Hydrochloride*	Anti-Cancer	PN	[1256580-46-7]	
Ambazone*	Oral Antiseptic	PN	[6011-12-7]	
Ambrisentan*	Anti-Hypertensive	PN	[177036-94-1]	
Angiotension-II Acetate*	Vasoconstrictor	PN	[4474-91-3] & [67724-26-9]	
Apixaban*	Anti-Coagulant	PN	[503612-47-3]	▲
Apremilast*	Anti-Psoriaic	PN	[608141-41-9]	
Aripiprazole*	Anti-Psychotic	USP	[129722-12-9]	
Azilsartan Medoxomil Potassium*	Anti-Hypertensive	PN	[863031-21-4]	
Bendamustine*	Anti-Cancer	PN	[16506-27-7]	▲

▲ USDMF

■ CEP

● EDMF

✦ JDMF

● Korean DMF

◆ Canadian DMF

* New products under development and are not meant for commercial sale

● PN - Producer's Norms

● All transactions are carried out in conformity with the patent laws applicable in the user country

Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Betiatide*	Diagnostic Agents Isotopes	PN	[103725-47-9]	
Biapenem*	Anti-Bacterial	PN	[120410-24-4]	
Bortezomib *	Anti-Cancer	PN	[179324-69-7]	▲ ●
Bosentan Monohydrate*	Cardiovascular	PN	[157212-55-0]	● ◆
Bosuinib*	Anti-Cancer	PN	[380843-75-4]	
Brivaracetam*	Anti-Epileptic	PN	[357336-20-0]	
Cabozaninib L-Malate*	Anti-Cancer	PN	[1140909-48-3]	
Calcium Oxybate*	Anti-Coagulant	PN	NA	
Canagliflozin*	Anti-Diabetic	PN	[842133-18-0]	▲
Carfilzomib*	Anti-Cancer	PN	[868540-17-4]	
Cariprazine Hydrochloride*	Anti-Depressant	PN	[1083076-69-0]	
Cetrorelix Acetate*	Infertility Agent	PN	[145672-81-7]	
Cariprazine Hydrochloride*	Calcimimetic	PN	[226256-56-0]	▲
Dabigatran Etxilate*	Anti-Coagulant	PN	[872728-81-9]	▲
Dalfampridine *	Multiple Sclerosis	PN	[45498-20-2]	▲

▲ USDMF ■ CEP ● EDMF ◆ JDMF ● Korean DMF ◆ Canadian DMF

* New products under development and are not meant for commercial sale

- PN - Producer's Norms
 - All transactions are carried out in conformity with the patent laws applicable in the user country
- Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer

NEW PRODUCTS

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Dapagliflozin*Citric Acid Co Crystal	Anti-Diabetic	PN	[461432-26-8]	
Dasatinib Monohydrate*	Anti-Cancer	PN	[302962-49-8]	
Difluprednate*	Anti-Inflammatory	PN	[23674-86-4]	
Dimethyl Fumarate*	Multiple Sclerosis	PN	[624-49-7]	▲
Dofetilide*	Anti-Arrhythmic	PN	[115256-11-6]	▲
Doxercalciferol*	Hyperparathyroidism	PN	[54573-75-0]	▲
Dronedarone*	Anti-Arrhythmic	PN	[141626-36-0]	▲
Droxidopa*	Anti-Parkinson	PN	[23651-95-8]	
Elagolix Sodium*	Antigonadotrophin	PN	[832720-36-2]	
Eluxadoline*	Gastrointestinal	PN	[864821-90-9]	
Empagliflozin*	Anti-Diabetic	PN	[864070-44-0]	▲
Enzalutamide*	Anti-Cancer	PN	[915087-33-1]	
Epoprostenol Sodium*	Pulmonary Arterial Hypertension	PN	[61849-14-7]	▲ ●
Eptifibatide*	Anti-Thrombotic	PN	[188627-80-7]	▲
Erlotinib Hydrochloride*	Anti-Cancer	PN	[183319-69-9]	▲

▲ USDMF

■ CEP

● EDMF

◆ JDMF

● Korean DMF

◆ Canadian DMF

* New products under development and are not meant for commercial sale

● PN - Producer's Norms

● All transactions are carried out in conformity with the patent laws applicable in the user country

Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Etelcalcetide HCl	Calcimimetic	PN	[1262780-97-1]	
Exenaide*	Anti-Diabetic	PN	[141732-76-5]	▲ ●
Ferric Carboxymaltose	Iron Replacement	PN	[9007-72-1]	
Fingolimod Hcl	Multiple Sclerosis	PN	[162359-56-0]	▲ ◆
Fosphenytoin Sodium*	Anti-Epileptic	USP	[92134-98-0]	▲
Fulvestrant	Anti-Cancer	EP/USP	[129453-61-8]	●
Ibrutinib*	Anti-Cancer	PN	[936563-96-1]	▲
Icatibant Acetate	Bradykini B2 Receptor Antagonist	PN	[138614-30-9]	▲
Irinotecan HCl Trihydrate	Anti-Cancer	PN	[136572-09-3]	▲
Ivacaftor	Cystic Fibrosis	PN	[873054-44-5]	
Ixazomib Citrate*	Anti-Cancer	PN	[1239908-20-3]	
Lanreotide Acetone Solvate	Somatostatin Analog	PN	[1441674-54-9]	
Ledipasvir	Anti-Viral	PN	[1190307-88-0]	
Lenalidomide*	Anti-Cancer	PN	[191732-72-6]	▲
Lenvatinib Mesylate*	Anti-Cancer	PN	[857890-39-2]	

▲ USDMF ■ CEP ● EDMF ◆ JDMF ◆ Korean DMF ◆ Canadian DMF

* New products under development and are not meant for commercial sale

- PN - Producer's Norms
 - All transactions are carried out in conformity with the patent laws applicable in the user country
- Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer

NEW PRODUCTS

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Levalbuterol Hydrochloride / Tartrate*	Anti-Asthmatic	PN	[50293-90-8]	▲
Levothyroxine Sodium*	Anti-Hypothyroidism	PN	[25416-65-3]	
Lifitegrast*	Dry Eye Syndrome	PN	[5967-78-5]	
Linaclotide*	Irritable Bowel Syndrome	PN	[851199-59-2]	▲
Linagliptin*	Anti-Diabetic	PN	[668270-12-0]	▲
Liothyronine Sodium*	Hormone Replacement	USP/EP	[55-06-1]	▲
Liraglutide (recombinant/synthetic)*	Anti-Diabetic	PN	[204656-20-2]	
Lubiprostone*	Management of Chronic Idiopathic Constipation	PN	[136790-76-6]	▲
Lumacaftor*	Cystic Fibrosis	PN	[936727-05-8]	
Lurasidone Hydrochloride*	Anti-Psychotic	PN	[367514-87-2]	▲
Metaxalone*	Muscle Relaxants	PN	[1665-48-1]	▲
Nilotinib Hydrochloride*	Anti-Cancer	PN	[923288-90-8]	
Nintedanib Esylate *	Idiopathic Pulmonary Fibrosis	PN	[656247-17-5]	
Niraparib Tosylate*	Anti-Cancer	PN	[1038915-73-9]	
Norepinephrine Bitartrate*	Hormone and Neurotransmitter	PN	[108341-18-0]	

▲ USDMF

■ CEP

● EDMF

✦ JDMF

● Korean DMF

◆ Canadian DMF

* New products under development and are not meant for commercial sale

● PN - Producer's Norms

● All transactions are carried out in conformity with the patent laws applicable in the user country

Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Omeprazole Mg	Antacid	USP	[95382-33-5]	▲
Palbociclib*	Anti-Cancer	PN	[571190-30-2]	
Paliperidone Palmitate*	Anti-Psychotic	PN	[199739-10-1]	▲
Pazopanib Hydrochloride*	Anti-Cancer	PN	[635702-64-6]	
Pimavaserin Tartrate*	Anti-Parkinson	PN	[706782-28-7]	
Plecanatide*	Guanylate Cyclase-C Agonist	PN	[467426-54-6]	
Pramlintide Acetate*	Anti-Diabetic	PN	[196078-30-5]	▲
Regadenoson*	Stress Agent	PN	[875148-45-1]	▲
Ribociclib*	Anti-Cancer	PN	[1211441-98-3]	
Rifaximin*	Anti-Infective	EP	[80621-81-4]	
Safinamide*	Anti-Parkinson	PN	[133865-89-1]	
Samidorphan*	Anti-Addiction	PN	[852626-89-2]	
Saxagliptin*	Anti-Diabetic	PN	[361442-04-8]	▲
Semaglutide*	Anti-Diabetic	PN	[910463-68-2]	
Sevelamer Hydrochloride*	Phosphate Binder	PN	[182683-007]	▲

▲ USDMF ■ CEP ● EDMF ✨ JDMF ● Korean DMF ◆ Canadian DMF

* New products under development and are not meant for commercial sale

- PN - Producer's Norms
- All transactions are carried out in conformity with the patent laws applicable in the user country
- Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



NEW PRODUCTS

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Silodosin*	Benign Prostatic Hyperplasia	JP	[160970-54-7]	
Sincalide*	Contrast Media	PN	[25126-32-3]	
Sitagliptin Fumarate*	Anti-Diabetic	PN	[486460-32-6]	▲
Sitagliptin Phosphate*	Anti-Diabetic	BP,USP	[654671-77-9]	
Sodium Oxybate*	Anti-Depressant	PN	[502-85-2]	
Sodium Zirconium Cyclosilicate*	Hyperkalemia	PN	[242800-27-7]	
Sorafenib Tosylate*	Anti-Cancer	PN	[4750207-59-1]	
Sunitinib Malate*	Anti-Cancer	PN	[341031-54-7]	
Teriparatide Acetate Synthetic, Recombinant*	Anti-Osteoporosis	PN	[52232-67-4]	
Tezacaftor*	Respiratory System	PN	[1152311-62-0]	
Ticagrelor*	Coagulation Inhibitors	PN	[274693-27-5]	
Tofacitinib Citrate*	Rheumatoid Arthritis	PN	[540737-29-9]	▲
Tofacitinib Oxalate*	Rheumatoid Arthritis	PN	NA	
Tolvaptan*	Metabolic Disorders	PN	[81846-19-7]	
Treprostinil*	Anti-Hypertension	PN	[81846-19-7]	

▲ USDMF

■ CEP

● EDMF

✦ JDMF

● Korean DMF

◆ Canadian DMF

* New products under development and are not meant for commercial sale

● PN - Producer's Norms

● All transactions are carried out in conformity with the patent laws applicable in the user country

Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer

Reaching People. Touching Lives.

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Vilanterol Trifenatate*	B2 Agonists	PN	[503070-58-4]	
Vildagliptin*	Anti-Diabetic	PN	[274901-16-5]	

▲ USDMF

■ CEP

● EDMF

✦ JDMF

◆ Korean DMF

◆ Canadian DMF

* New products under development and are not meant for commercial sale

- PN - Producer's Norms
- All transactions are carried out in conformity with the patent laws applicable in the user country
- Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Amisulpride	Anti-Psychotic	EP	[71675-85-9]	■
Amorolfine Hydrochloride	Dermatology	EP	[78613-38-4]	●
Anastrozole	Anti-Cancer	EP	[120511-73-1]	▲ ● ◆
Atazanavir Sulfate	Anti-Viral	PN	[229975-97-7]	▲
Atorvastatin Calcium	Cardiovascular	USP/EP	[134523-03-8]	▲ ■ ● ◆
Atosiban Acetate	Oxytocin Antagonist	EP	[914453-95-5]	●
Benazepril Hydrochloride	Cardiovascular	EP/USP	[86541-74-4]	■
Bicalutamide	Anti-Androgen	EP/USP	[90357-06-5]	▲ ● ◆
Bivalirudin	Anti-Coagulant	PN	[128270-60-0]	▲
Budesonide	Anti-Inflammatory	EP/USP	[51333-22-3]	▲ ◆
Buprenorphine	Pain Management	EP/USP	[952485-79-7]	▲ ■ ●
Bupropion Hydrochloride	Anti-Depressant	EP/USP	[31667-93-7]	▲
Calcitonin (salmon)	Anti-Osteoporosis	EP/USP	[9007-12-9]	
Candesartan Cilexetil	Cardiovascular	EP/USP	[145040-37-5]	■ ◆
Capecitabine	Anti-Cancer	USP	[154361-50-9]	▲ ■ ● ◆

▲ USDMF

■ CEP

● EDMF

◆ JDMF

● Korean DMF

◆ Canadian DMF

* New products under development and are not meant for commercial sale

● PN - Producer's Norms

● All transactions are carried out in conformity with the patent laws applicable in the user country

Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Carboplatin	Anti-Cancer	EP/USP	[41575-94-4]	▲ ■ ◆
Cefpodoxime Proxetil	Antibiotic	PN	[87239-81-4]	
Cefprozil Monohydrate	Anti-Infective	USP	[121123-17-9]	◆
Cefuroxime Axetil	Antibiotic	EP/USP	[64544-07-6]	■
Cilastatin Sodium	Anti-Infective	EP/USP	[81129-83-1]	■ ◆
Cilazapril	Anti-Hypertensive	EP	[92077-78-6]	■ ◆
Cisplatin	Anti-Cancer	EP/USP	[15663-27-1]	■ ◆
Ciprofloxacin Hydrochloride	Antibiotic	EP	[86393-32-0]	■ ◆
Clarithromycin Powder/ Granules	Anti-Infective	EP/USP	[81103-11-9]	■ ◆
Clomipramine Hydrochloride	Anti-Depressant	EP/USP	[17321-77-6]	■ ◆
Clonazepam	Anti-Epileptic	EP/USP	[1622-61-3]	■ ● ◆
Deferasirox*	Iron Chelator	PN	[201530-41-8]	▲ ◆
Desloratadine	Anti-Histamine	EP	[100643-71-8]	■
Divalproex Sodium	Anti-Epileptic	USP	[76584-70-8]	▲
Donepezil Hydrochloride	Anti-Alzheimer	USP	[142057-77-0]	▲

▲ USDMF ■ CEP ● EDMF ◆ JDMF ● Korean DMF ◆ Canadian DMF

* New products under development and are not meant for commercial sale

- PN - Producer's Norms
 - All transactions are carried out in conformity with the patent laws applicable in the user country
- Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Doripenem*	Anti-Bacterial	PN	[364622-82-2]	
Drospirenone	Oral Contraceptive	EP/USP	[67392-87-4]	▲
Emtricitabine*	Anti-Viral	PN	[143491-57-0]	
Entecavir	Anti-Viral	EP	[209216-23-9]	●
Ertapenem Sodium*	Anti-Bacterial	PN	[153773-82-1]	▲ ●
Escitalopram Oxalate	Anti-Depressant	USP	[219861-08-2]	
Esomeprazole Mg (Amorphous)	Anti-Ulcerative	USP	[161973-10-0]	▲ ● ◆
Esomeprazole Mg Trihydrate	Anti-Ulcerative	USP	[217087-09-7]	▲
Esomeprazole Sodium	Proton Pump Inhibitor	PN	[161796-78-7]	▲ ● ◆
Exemestane	Anti-Cancer	PN	[107868-30-4]	▲
Fexofenadine Hydrochloride	Antihistmine	USP	[138452-21-8]	■
Fluticasone Propionate	Anti-Inflammatory	EP/USP	[80474-14-2]	■
Fluvastain Sodium	Cardiovascular	EP	[93957-55-2]	■
Fluvoxamine Maleate	Anti-Depressant	EP/USP	[61718-82-9]	▲ ★ ◆
Gabapentin	Anti-Convulsant	PN	[60142-96-3]	▲

▲ USDMF

■ CEP

● EDMF

★ JDMF

◆ Korean DMF

◆ Canadian DMF

* New products under development and are not meant for commercial sale

● PN - Producer's Norms

● All transactions are carried out in conformity with the patent laws applicable in the user country

Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Ganirelix Acetate	Infertility Agent	PN	[129311-55-3]	▲
Gemcitabine Hydrochloride	Anti-Cancer	EP/USP	[122111-03-9]	▲ ■ ✨ ◆
Hydroxyprogesterone Caproate*	Steroidal Progestin	PN	[630-56-8]	▲
Imatinib Mesylate*	Anti-Cancer	PN	[220127-57-1]	▲ ◆
Imipenem	Anti-Bacterial	EP/USP	[74431-23-5]	■ ◆
Irbesartan	Cardiovascular	EP/USP	[138402-11-6]	■ ◆
Isotretinoin	Anti-Acne	EP/USP	[4759-48-2]	▲ ■ ◆
Lacosamide	Anti-Epileptic	EP	[175481-36-4]	●
Lansoprazole	Antacid	EP	[103577-45-3]	■
Lercanidipine Hydrochloride	Anti-Hypertensive	PN	[132866-11-6]	◆
Letrozole	Anti-Cancer	EP/USP	[112809-51-5]	▲ ■ ◆
Leuprolide Acetate	Anti-Cancer	PN	[74381-53-6]	■
Levetiracetam	Anti-Epileptic	EP/USP	[102767-28-2]	▲ ● ◆
Losartan Potassium	Anti-Hypertensive	PN	[124750-99-8]	■ ◆
Loteprednol Etabonate	Seasonal Allergic Conjunctivitis	PN	[82034-46-6]	

▲ USDMF ■ CEP ● EDMF ✨ JDMF ◆ Korean DMF ◆ Canadian DMF

* New products under development and are not meant for commercial sale

- PN - Producer's Norms
 - All transactions are carried out in conformity with the patent laws applicable in the user country
- Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Luliconazole*	Anti-Fungal	PN	[187164-19-8]	
Magnesium Valproate	Anti-Epileptic	PN	[62959-43-7]	
Meloxicam	NSAID	EP/USP	[71125-38-7]	■ ■ ■
Meropenem	Anti-Bacterial	EP/JP/USP	[119478-56-7]	■ ■ ■ ■ ■
Mesalamine	Anti-Inflammatory	EP/USP	[89-57-6]	▲ ■
Metadoxine*	Alcohol Abuse	PN	[74536-44-0]	
Metformin	Anti-Diabetic	EP/USP	[1115-70-4]	▲ ■ ■ ■ ■ ■
Methylphenidate Hydrochloride	CNS Simulant	EP	[298-59-9]	■ ■
Metoprolol Succinate	Anti-Hypertensive	EP/USP	[98418-47-4]	▲ ■
Metoprolol Tartrate	Anti-Hypertensive	EP/USP	[56392-17-7]	▲ ■ ■ ■
Midazolam	Anti-Anxiety	EP/USP	[59467-70-8]	■ ■ ■
Mirtazapine	Anti-Depressant	PN	[85650-52-8]	■
Naltrexone Hydrochloride	Opioid Antagonist	EP/USP	[16676-29-2]	▲ ■
Naloxone Hydrochloride	Opioid Antagonist	EP/USP	[357-08-4]	▲ ■
Octreotide Acetate	Anti-Cancer	USP	[79517-01-4]	▲ ■ ■ ■

▲ USDMF

■ CEP

● EDMF

◆ JDMF

■ Korean DMF

◆ Canadian DMF

* New products under development and are not meant for commercial sale

● PN - Producer's Norms

● All transactions are carried out in conformity with the patent laws applicable in the user country

Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Ofloxacin	Anti-Infective	EP/USP	[82419-36-1]	■ ◆
Olanzapine	Anti-Psychotic	EP	[132539-06-1]	■ ◆
Ondansetron Base / Hydrochloride	Anti-Emetic	USP	[116002-70-1]	▲ ■ ● ◆
Orlistat	Anti-Obesity	PN/USP	[96829-58-2]	●
Oxaliplatin	Anti-Cancer	EP/USP	[61825-94-3]	▲ ■ ★ ◆
Oxetacaine	Potent Local Anesthetic	PN	[126-27-2]	
Oxcarbazepine	Anti-Epileptic	EP/USP	[28721-07-5]	▲
Paliperidone*	Anti-Psychotic	PN	[144598-75-4]	▲
Pamidronate Disodium	Anti-Osteoporosis	EP/USP	[109552-15-0]	
Pantoprazole Sodium	Proton Pump Inhibitor	EP/USP	[138786-67-1]	▲ ■ ● ◆
Paroxetine Hydrochloride	Anti-Depressant	BP/EP	[78246-49-8]	▲
Pemetrexed Disodium*	Anti-Cancer	PN	[150399-23-8]	▲ ● ◆
Pentazocine	Opioid Analgesic	IP/PN	[359-83-1]	
Pentoxifylline	Anti-Anginal	EP/USP	[6493-05-6]	▲ ■ ◆
Phentermine Hydrochloride	Appete Suppressant	USP	[1197-21-3]	◆

▲ USDMF ■ CEP ● EDMF ★ JDMF ◆ Korean DMF ◆ Canadian DMF

* New products under development and are not meant for commercial sale

- PN - Producer's Norms
 - All transactions are carried out in conformity with the patent laws applicable in the user country
- Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Pregabalin*	Anti-Epileptic	PN	[148553-50-8]	▲ ●
Queiapine Fumarate	Anti-Psychotic	PN	[111974-72-2]	▲ ●
Rabeprazole Sodium	Antacid	EP	[117976-90-6]	● ◆
Ranolazine*	Anti-Anginal	PN	[95635-55-5]	▲
Repaglinide	Anti-Diabetic	EP	[135062-02-1]	■ ◆
Rivastigmine Tartrate / Base	Anti-Parkinsons	EP/USP	[129101-54-8]	▲ ●
Rosuvastain Calcium	Cardiovascular	EP	[147098-20-2]	▲ ■ ● ◆
Sertraline Hydrochloride	Anti-Depressant	EP	[79559-97-0]	■
Sevelamer Carbonate	Anti-Hyperphosphatemia	PN	[845273-93-0]	▲
Simvastatin	Anti-Hypertensive	EP	[79902-63-9]	■ ◆
Sodium Valporate	Anti-Epileptic	EP/USP	[1069-66-5]	■ ◆
Solifenacin Succinate	Anti-Muscarinic	EP	[242478-38-2]	■ ◆
Sumatriptan Succinate	Anti-Migraine	EP/USP	[103628-48-4]	▲ ■ ◆
Tamsulosin Hydrochloride	Benign Prostaic Hyperplasia	EP/USP	[106463-17-6]	■ ◆
Telmisartan	Anti-Hypertensive	EP	[144701-48-4]	■ ◆

▲ USDMF

■ CEP

● EDMF

◆ JDMF

● Korean DMF

◆ Canadian DMF

* New products under development and are not meant for commercial sale

● PN - Producer's Norms

● All transactions are carried out in conformity with the patent laws applicable in the user country

Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Temozolomide	Anti-Cancer	USP	[85662-93-1]	▲ ● ■ ◆
Terlipressin Acetate	Vasopressin Analogue	PN	[14636-12-5]	●
Testosterone Cypionate	Hormone Replacement	USP	[58-20-8]	▲
Testosterone Undecanoate	Hormone Replacement	USP	[5949-44-0]	◆
Testosterone USP	Hormone	EP/USP	[58-22-0]	▲ ◆
Tetrabenazine	Hyperkineic Movement Disorders	USP	[58-46-8]	▲
Tiagabine Hydrochloride	Anti-Epileptic	USP	[145821-59-6]	▲
Tigecycline*	Anti-Bacterial	PN	[220620-09-7]	
Tizanidine Hydrochloride	Muscle Relaxant	USP	[64461-82-1]	▲ ● ◆
Topiramate	Anti-Epileptic	USP	[97240-79-4]	▲ ● ■ ◆
Tramadol Hydrochloride	Opioid Analgesic	EP/USP	[36282-47-0]	▲ ■ ✨ ■ ◆
Valacyclovir Hydrochloride	Anti-Viral	EP/USP	[124832-27-5]	▲ ●
Valganciclovir Hydrochloride	Anti-Viral	PN	[175865-59-5]	●
Valproic Acid	Anti-Epileptic	EP/USP	[99-66-1]	▲ ■
Valsartan	Cardiovascular	EP/USP	[137862-53-4]	■ ◆

▲ USDMF ■ CEP ● EDMF ✨ JDMF ■ Korean DMF ◆ Canadian DMF

* New products under development and are not meant for commercial sale

- PN - Producer's Norms
 - All transactions are carried out in conformity with the patent laws applicable in the user country
- Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Venlafaxine Hydrochloride	Anti-Depressant	EP	[993004-78-4]	■ ◆
Zoledronic Acid	Anti-Osteoporosis	PN	[118072-93-8]	▲ ● ◆
Zolmitriptan	Anti-Migraine	PN	[139264-17-8]	▲
Zolpidem Tartrate	Hypnotic	EP/USP	[99294-93-6]	■

▲ USDMF

■ CEP

● EDMF

✦ JDMF

◆ Korean DMF

◆ Canadian DMF

* New products under development and are not meant for commercial sale

• PN - Producer's Norms

• All transactions are carried out in conformity with the patent laws applicable in the user country

Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



ALKALOID PRODUCTS

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Acenocoumarol	Anti-Coagulant	Ph.Hg.	[152-72-7]	x
Buspirone Hydrochloride	Anxiolytics	EP/USP	[33386-08-2]	
Codeine Base	Analgesic	BP/EP	[6059-47-8]	
Codeine Hydrochloride	Analgesic	BP/EP	[5916-29-0]	
Codeine Phosphate Hemihydrate	Analgesic	BP/EP/	[41444-62-6]	■●◆
Dihydrocodeine Hydrogentartrate	Analgesic	BP/EP	[5965-13-9]	■●◆
Ethylmorphine Hydrochloride	Analgesic	BP/EP	[6746-59-4]	
Hydroxychloroquine Sulphate	Anti-Malarial	USP	[747-36-4]	▲
Morphine Sulphate	Analgesic	BP/EP	[6211-15-0]	
Noscapine Base	Anti-Tussive	BP/EP	[128-62-1]	●
Noscapine Hydrochloride	Anti-Tussive	BP/EP	912-60-7]	●
Oxycodone Hydrochloride	Analgesic	EP	[124-90-3]	■●
Phenobarbital Acid	Anti-Epileptic	BP/EP/	[50-06-6]	▲■●
Phenobarbital Sodium	Anti-Epileptic	BP/EP	[57-30-7]	▲◆
Pholcodine	Anti-Tussive	BP/EP	[509-67-1]	●

▲ USDMF

■ CEP

● EDMF

◆ JDMF

◆ Korean DMF

◆ Canadian DMF

* New products under development and are not meant for commercial sale

● PN - Producer's Norms

● All transactions are carried out in conformity with the patent laws applicable in the user country

Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



CHATTEM PRODUCTS

Product	Therapeutic Category	Specs	CAS No.	DMF Status
D-Amphetamine Base	CNS Simulant	PN	[51-64-9]	
D-Amphetamine Sulfate	CNS Simulant	USP	[51-63-8]	
DL-Amphetamine Sulfate	CNS Simulant	PN	[60-13-9]	
D-Amphetamine Saccharate	CNS Simulant	PN	[300666-47-1]	
DL-Amphetamine Aspartate	CNS Simulant	PN	[25333-81-7]	
Ammonium Lactate	Topical Skin Use	USP	[515-98-0]	
Benzphetamine Hydrochloride	Weight Loss	PN	[5411-22-3]	▲
Buprenorphine Hydrochloride	Pain Management	PN	[53152-21-9]	
Butalbital	Depressant	USP	[77-26-9]	▲ ●
Butabarbital Base	CNS Depressant	USP	[125-40-6]	
Butabarbital Sodium	CNS Depressant	USP	[143-81-7]	▲
Codeine Phosphate	Pain Management	PN	[52-28-8]	
Calcium Oxybate	Anti-Coagulant	PN	[82316-97-0]	
Dihydrocodeine	Pain Management	PN	[125-28-0]	
Fentanyl Base	Pain Management	USP/EP/IP	[437-38-7]	▲

▲ USDMF

■ CEP

● EDMF

◆ JDMF

◆ Korean DMF

◆ Canadian DMF

* New products under development and are not meant for commercial sale

● PN - Producer's Norms

● All transactions are carried out in conformity with the patent laws applicable in the user country

Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



CHATTEM PRODUCTS

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Fentanyl Citrate	Pain Management	USP/EP/IP	[990-73-8]	▲
Glycine	Used in IV solutions	USP/EP	[56-40-6]	▲
Hydrocodone Bitartrate	Pain Management	USP	[143-71-5]	▲
Hydromorphone Hydrochloride	Pain Management	USP	[71-68-1]	▲
Hydroxyamphetamine HBr	Ophthalmic Solution	USP	[306-21-8]	▲
Levmetamphetamine	Vasoconstrictor	USP	[33817-09-03]	
Levorphanol Tartrate	Pain Management	PN	[125-72-2]	
Lisdexamphetamine	CNS Simulant	PN	[608137-32-2]	
Methamphetamine Hydrochloride (Unmilled)	CNS Simulant	USP	[51-57-0]	
Methamphetamine Hydrochloride (Milled)	CNS Simulant	USP	[51-57-0]	▲
Methylphenidate Base	CNS Simulant	USP/EP	[113-45-1]	▲
Methylphenidate Hydrochloride	CNS Simulant	USP	[298-59-9]	▲
D-Methylphenidate Base	CNS Simulant	USP	[40421-64-9]	
D-Methylphenidate Hydrochloride	CNS Simulant	USP	[19262-68-1]	▲
Methenamine	Anti-Bacterial	USP	[100-97-0]	

▲ USDMF

■ CEP

● EDMF

✦ JDMF

● Korean DMF

◆ Canadian DMF

* New products under development and are not meant for commercial sale

● PN - Producer's Norms

● All transactions are carried out in conformity with the patent laws applicable in the user country

Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



SUN AUSTRALIA PRODUCTS

Product	Therapeutic Category	Specs	CAS No.	DMF Status
Codeine	Narcotic Raw Material	PN	[76-57-3]	
Codeine Phosphate Hemihydrate	Analgesic	EP/USP	[41111-62-6]	■ ●
Morphine	Narcotic Raw Material	PN	[57-27-2]	
Noscapine	Anti-Tussive	PN	[128-62-1]	
Oripavine	Narcotic Raw Material	PN	[467-04-9]	
Thebaine	Narcotic Raw Material	PN	[115-37-7]	

▲ USDMF

■ CEP

● EDMF

✦ JDMF

◆ Korean DMF

◆ Canadian DMF

* New products under development and are not meant for commercial sale

● PN - Producer's Norms

● All transactions are carried out in conformity with the patent laws applicable in the user country

Responsibility with respect to third party's patent rights in a specific country lies exclusively with the Buyer



GLOBAL PRESENCE



- ★ GLOBAL HEADQUARTERS
- 🧪 R&D CENTERS
- API & FORMULATION PLANTS

- API PLANTS
- FORMULATION PLANTS



[Map Not To Scale]



Sun House, Plot No 201 B/1 Western Express Highway, Goregaon East, Mumbai 400 063, Maharashtra (India)

Tel: +91 22 4324 4324 Email: apimarketing@sunpharma.com

www.sunpharma.com